2Jorge D. Ursodeoxy cholic acid inhibits induction of the human intestinal epithelial nitric oxide synthase [ J ]. Hepatology, 1995,22 ( 4 ) : 361.
3叶维法 主编.临床肝胆病学[M].天津：天津科学技术出版社,1983.942-945.
4Prince M, Chetwynd A, Newman W, et al. survid and sympton Progerssion in a geographically based cohort of patients with primary biliary cirrhosis: follow - up for up to 28 years [ J]. Castroenterology, 2002,123(4) : 1044 - 1051.
5Dickson ER, Grambasch PM, Fleming TR,et al. Prognosis in Primary biliary cirrhosis: model for decision making [ J ]. Hepatoiogy, 1989, 10(1):1-7.
6Heathcote EJ. Management of primary biliary cirrhosis. The AmeriAssociation for the study of Liver Diseases practice guidelines [ J ]. Hepatology,2000,31 ( 4 ) : 1005 - 1013.
7Lazaridis KN, Gores G J, Lindor KD. Uresodeoxy cholic acid mechamism of action and clinical use in hepatobiliary disorders[ J]. Hepatol, 2001,35: 134 - 146.
8Paumgartner G, Beucerss U. Ursodoxy cholic acid in cholestatic liver disease:mechanism of acion and therapeutic use revisited[ J]. Hepatology,2002,36: 525 - 531.
9Pares A, Caballeria L, Rodes J, et al. Long - term effects of ursodeoxycholic acid in primary biliary cirrhosis:results of a double - blind controlled multicen tric trial[ J]. Hepatol,2000,32:561 - 566.
10Poupon RE, Lindor Kn, Pares A, et al. Combined analysis of the effect of treatment with ursodeoxy cholic acid on histologic progression in primary biliary cirrhosis [ J ]. Hepatol,2003,39: 12 - 16.
二级参考文献10
1Fan LY,Zhong RQ,Kong XT,et al.Study on the relationship of CTLA-4-318,+ 49 polymorphisms with autoimmune hepatitis and primary biliary cirrhosis in a Chinese population.Zhonghua Yi Xue Yi Chuan Xue Za Zhi,2004,21:440-443.
2Daimon Y,Yamanishi K,Murakami Y,et al.Novel single nucleotide polymorphisms of the cytokeratin 19 pseudogene are associated with primary biliary cirrhosis.Hepatol Res,2003,25:281-286.
3Matsushita M,Miyakawa H,Tanaka A,et al.Single nucleotlde polymorphisms of the mannose-binding lectin are associated with susceptibility to primary biliary cirrhosis.J Autoimmun,2001,17:251-257.
4Donaldson P,Agarwal K,Craggs A,et al.HLA and interleukin 1 gene polymorphisms in primary biliary cirrhosis:association with disease progression and disease susceptibility.Gut,2001,48:397-402.
5Selmi C,Zuin M,Biondi ML,et al.Genetic variants of endothelial nitric oxide synthase in patients with primary biliary cirrhosis:association with disease severity.J Gastroenterol Hepatol,2003,18:1150-1155.
7Bittencourt PL,Palacios SA,Farias AQ,et al.Analysis of major histocompatibility complex and CTLA-4 alleles in Brizulian patients with primary biliary cirrhosis.J Gastroenterol Hepatol,2003,18:1061-1066.
8Invernizzi P,Battezzati PM,Crosignani A,et al.Peciliar HLA polymorphisms in Italian patients with primary biliary cirrhosis.J Hepatol,2003,38:401-406.
9Matsushita M,Tanaka A,Kikuchi K,et al.Association of single nucleotide polymorphisms of the interleukin-10 promoter gene and susceptibility to primary biliary cirrhosis:immunogenetic differences in Italian and Japanese patients.Autoimmunity,2002,35:531-536.
10Komuro O,Takahashi H,Sato K,et al.Significance of serum oxidative stress related markers and genotype of GST gene in the pathogeneses of primary biliary cirrhosis.Nihon Rinsho Meneki Gakkai Kaishi,2004,27:322-329.
